Virtual Library
Start Your Search
Lu Yang
Author of
-
+
P1.11 - Screening and Early Detection (ID 177)
- Event: WCLC 2019
- Type: Poster Viewing in the Exhibit Hall
- Track: Screening and Early Detection
- Presentations: 1
- Moderators:
- Coordinates: 9/08/2019, 09:45 - 18:00, Exhibit Hall
-
+
P1.11-12 - Genetic Landscape and Immune Microenvironment Features in Recurrence in Stage IA of Lung Adenocarcinoma (ID 2503)
09:45 - 18:00 | Presenting Author(s): Lu Yang
- Abstract
Background
Lung adenocarcinoma (LUAD) leads to majority of lung cancer deaths. Various somatic mutations and copy number variations have been reported in LUAD, but their relevance to clinical prognosis of early stage LUAD is poorly understood. Besides, nearly 30% of patients with stage IA NSCLC eventually die of recurrence or metastasis in spite of the use of standard staging procedures. This study was designed to explore the genomic landscape in stage IA LUAD patients and find immune microenvironment features in recurrences.
Method
43 eligible stage IA LUAD patients with radical surgery and without adjuvant therapy from Cancer Hospital, Chinese Academy of Medical Science and Peking Union Medical College were included in this study. Up to last follow-up in April 9th, 2018, 22 patients were relapsed and 21 were not recurrent. Clinical data were collected in the baseline data analysis. Whole-exome sequencing and RNA IO panel sequencing were performed in tumor and normal lung tissues.
Result
There were no significant differences in terms of clinical and pathological features comparing recurrences to non-recurrences. The most common mutated genes were TP53(48%), EGFR (18%) and KRAS (9%). Tumor mutation burden (TMB) values ranged from 0.2 to 16.4 Mutations/Mb, with a median of 2.5Mutations/Mb. Twenty-two differential genes were screened out and classified to five signatures in terms of its function. These five signatures including tumor cell proliferation, tumor antigen, cytotoxic T cells activity, T lymphocyte chemotactic factor, and natural killer cell activation were dramatically high expressed in non-recurrences (p＜0.05). Besides, cytolytic activity was significantly higher in non-recurrences (p＜0.05), which were represented as the log-average expression of GZMA and PRF1. Furthermore, six genes out of twenty-two genes were found to be significantly important in terms of disease-free survival (DFS) in stage IA LUAD with radical resection according to Kaplan-Meier analysis. However, there was no relation between TMB and DFS (p=0.501).
Conclusion
This is the first study reporting the relation of gene landscape and immune microenvironment features with prognosis in stage IA LUAD after curative resection. Host immunity is significantly related with the recurrence, whereas tumor mutation and TMB were not. Six genes related with host immunity have been found and promised to be novel prognostic factors in prognosis of stage IA LUAD.
-
+
P2.14 - Targeted Therapy (ID 183)
- Event: WCLC 2019
- Type: Poster Viewing in the Exhibit Hall
- Track: Targeted Therapy
- Presentations: 1
- Moderators:
- Coordinates: 9/09/2019, 10:15 - 18:15, Exhibit Hall
-
+
P2.14-01 - Real World Treatment Outcomes in Chinese Patients with RET-Rearranged Lung Cancer (ID 2471)
10:15 - 18:15 | Presenting Author(s): Lu Yang
- Abstract
Background
One global, multicenter study has identified available multi-targeted kinase inhibitors has limited activity in patients with RET-rearranged non-small-cell lung cancer (NSCLC). However, there is limited molecular and clinical data with RET-rearranged NSCLC in China.
Method
Retrospective real-world analysis of clinical, molecular, and treatment outcome of a web-based patient registry and hospital chart review in China.
Result
By 28/03/2019, 73 patients with RET-rearranged lung cancers from multiple hospitals in China were registered. The majority of patients were female (56.5%), never smokers (62.9%) with NSCLCs (98.4%). 15 different molecular subtypes of infusion partners were identified in which twelve subtypes were not reported before. KIF5B-RET was the most common (51.6%) followed by CCDC8-RET (25.8%). Two patients coexist with ALK fusion, one patient with EGFR mutation, and one patient with C-MET amplification. Median OS was 20.8m (95%CI 14.9-96.4) for 46 stage IV NSCLCs. Median PFS was 7.0m (95%CI 2.7-11.7) in patients who received 1st-line treatment including chemotherapy and multi-targeted kinase inhibitors. Patients with CNS (N=14, 30.4%) had significantly shorter PFS with those without CNS (N=32, 69.6%) (4.4m vs 9.1m; p=0.04, HR 2.343[1.040-5.279]). There was no statistically significant difference in PFS in terms of upstream fusion partners (KIF5B v other partner) (p=0.059). Besides, sixteen patients received one or more lines multi-targeted kinase inhibitors: cabozantinib (fourteen patients), vandetanib (two patients) and anlotinib (three patients). The median line of systemic therapy of the first RET TKI administered was as second line (range, first to third line). The median PFS of multi-targeted kinase inhibitor therapy in patients with CNS was 9.0m (95%CI 2.5-15.5m).
Conclusion
This is the first real-world study reporting clinical outcomes of Chinese RET-rearranged advanced NSCLC patients by now, which included the most samples, either. Most patients received chemotherapy with unfavorable survival, although several patients may benefit more from available multi-targeted kinase inhibitors. CNS is an important risk factor whereas upstream fusion partners are not. More and novel targeted therapies for RET-rearranged patients are urgently needed in China.
